FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely, to therapy, and concerns the treatment of lysosomal storage diseases. For this, an enzyme, the etiologic insufficiency of which is present in this disease, is intraventricularly injected. Injection is performed over a period of more than three hours.
EFFECT: such a slow injection provides the maximum therapeutic effect, which consists in reducing the pathological level of metabolites in lysosomes of brain tissues and in internal organs.
13 cl, 11 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INTRAVENTRICULAR DELIVERY OF ENZYMES IN CASE OF LYSOSOMAL STORAGE DISEASES | 2007 |
|
RU2529830C2 |
| SLOW INTRAVENTRICULAR DELIVERY | 2007 |
|
RU2452368C2 |
| ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO CENTRAL NERVOUS SYSTEM | 2014 |
|
RU2692251C2 |
| PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS AGAINST LYSOSOMAL STORAGE DISEASES | 2017 |
|
RU2749515C2 |
| ADENO-ASSOCIATED VIRUS-MEDIATED GENE TRANSFER INTO THE CENTRAL NERVOUS SYSTEM | 2014 |
|
RU2801511C1 |
| ADENO-ASSOCIATED VIRUS VECTOR FOR THERAPEUTIC DELIVERY INTO THE CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2751952C2 |
| VECTOR BASED ON ADENO-ASSOCIATED VIRUS FOR THERAPEUTIC DELIVERY TO CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2804953C2 |
| DRUG FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY AND A METHOD FOR ITS TREATMENT | 2021 |
|
RU2769577C1 |
| METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE | 2011 |
|
RU2660348C2 |
| METHODS AND COMPOSITIONS FOR DELIVERY OF IDURONATE-2-SULPHATASE TO CNS | 2011 |
|
RU2774112C2 |
